



A Review of Marine Natural Product Resources with Potential Bioactivity Against SARS-COV-2

Neha Mishra¹, Ena Gupta², Angelo Mark P. Walag^{3,4,5*}, Ravindra N. Kharwar⁵, Priyanka Singh⁶, Pragya Mishra⁷

¹Department of Food, Nutrition and Public Health, SHUATS, Prayagraj 211007 India

²Department of Home Science, University of Allahabad, Prayagraj, 211001 India

³Department of Science Education, University of Science and Technology of Southern Philippines, Cagayan de Oro City, 9000 Philippines

⁴Regular Member, Division of Biological Sciences, National Research Council of the Philippines, Philippines

⁵Mycopathology and Microbial Techniques Laboratory, Department of Botany, Banaras Hindu University, Varanasi, 221005 India

⁶Centre of Food Technology, University of Allahabad, Prayagraj, 211002 India

⁷Food Processing and Management, DDU Kaushal Kendra, RGSC, Banaras Hindu University, Varanasi, 221005 India

ARTICLE INFO

Article history:

Received 16 December 2022

Revised 05 January 2023

Accepted 06 January 2023

Published online 01 February 2023

Copyright: © 2023 Mishra *et al.* This is an open-access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The emergence of new pathogenic viruses and the constant outbreak of viral diseases have created an upsurge in novel antiviral agents. Marine natural products are the most unexplored reservoir of novel, biologically active, chemically diverse compounds. A systematic literature review was conducted using PRISMA guidelines, accessing four major databases; PubMed, Science Direct, Scopus, and Google Scholar. Numerous studies supported the robust antiviral activity of marine resources against drug-resistant viruses such as SARS, Ebola, Influenza, and HIV. However, adequate research on marine resources for developing anti-covid therapy is lacking. The aim of the review was to explore the marine resources and their compounds that could lead to developing an effective antiviral drug. We also highlighted the current status of novel compounds against different species of corona family and discussed the future prospects of marine resources against COVID-19 management.

Keywords: Antiviral agent, marine resource, Covid-19, bioactive compound, SARS-CoV-2.

Introduction

Safeguarding public health has become a critical issue due to the emergence of new viral infections such as SARS Cov, MERS Cov, and COVID-19 infections, which have compromised human survival. Recently, the Covid-19 pandemic has broken out and led to 466,871 deaths till 21 June 2020.^{1,2} Despite the progress made in immunization and drug development, no drug or vaccine has yet been discovered. Although, intensive studies are going around the world to find novel drugs to combat the mutant virus of the corona family. It is urgent to explore alternate antiviral therapies, including several natural products and herbal medicines, against such deadly viral infections.^{3,4} The ocean provides enormous opportunities to discover new compounds as it has more than 13,000 molecules, out of which 3000 have active properties.^{5,6} The ocean accounts for 75% of the world and has an enormous range of biodiversity, which are still unexplored.^{7,8} Marine organisms produce unique chemical compounds that embrace polysaccharides, amino acids, glycosides, phenolic compounds, alkaloids, terpenoids, peptides, steroids, halogenated ketones, and polyketides to cope the diverse environmental condition and to protect themselves from predators.⁹ Marine resources account for 50% of the earth's total diversity, with only a few (0.01%-0.1%) identified and much to investigate. This constitutes the marine organism as a valuable resource for novel compounds, and much consideration has been derived from developing new drugs to combat the SARS-CoV-2 virus.²

In Asian countries, there is a long history of the extensive usage of marine macro and microalgae as functional foods and medicinal purposes. Marine resources' antiviral and antibacterial activity have been known for thousands of years. Much of the recent findings revealed the antiviral potential of marine resources against different pathogenic viruses such as human immunodeficiency virus-1 (HIV-1), herpes simplex virus-2 (HSV-2), Junin virus (JV), poliovirus (PV), severe acute respiratory syndrome (SARS) virus, measles virus, and influenza virus.^{10,11} However, there are still gaps in our knowledge of their activities. Marine resources constitute a vast untapped reservoir of highly diverse and unique natural products with wide-ranging biological action. This motivated studies on *in vitro*, *in vivo*, and clinical analyses on the antiviral activity of marine resources to develop new antiviral drugs and pave the way to create new drugs against the new COVID-19 infections. This review aimed to screen the marine resources and their compounds that could lead to developing effective antiviral drugs. We highlighted the antiviral activity of novel compounds against different drug-resistant viruses and discussed the prospects of marine resources against COVID-19 management.

The exploitation of antiviral compounds from Marine Resources

Antiviral compounds from marine bacteria

One of the promising sources of therapeutic drugs is marine organisms. Research suggests that very few studies have been performed on antiviral compounds derived from marine bacteria. The marine bacterial exopolysaccharides (EPS) were the source of antiviral compounds produced by many bacteria to survive in adverse conditions, approach for growth, and attachment to solid surfaces.¹² Researchers are trying to explore new exopolysaccharides from extreme marine environment bacteria that can tolerate intense temperature, pressure, high concentrations of heavy metals, and H₂S production.¹³ Some deep-sea bacteria that survive in an extreme environment include strain HYD721, *Alteromonas macleodii* subsp. *fijiensis*, *Alteromonas infernus* and *Vibrio diabolicus*.¹² There is a diverse application of these bacterial EPS in distinct industrial fields as they possess novel chemical compositions, structures, and properties. In *Pseudomonas* sp., a bioactive compound

*Corresponding author. E mail: walag.angelo@gmail.com
Tel: +63917-7000-485

Citation: Mishra N, Gupta E, Walag AMP, Kharwar RN, Singh P, Mishra P. A Review of Marine Natural Product Resources with Potential Bioactivity Against SARS-COV-2. Trop J Nat Prod Res. 2023; 7(1):2093-2103. <http://www.doi.org/10.26538/tjnpr/v7i1.2>

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria.

named glycosaminoglycan was explored, exhibiting antiviral potential against influenza virus A and B.¹⁴ According to Rinker and Kelly,¹⁵ extra polysaccharides were produced by hydrothermophilic *Thermococcus litoralis* and *Thermotoga maritima*.

Exopolysaccharides

A significant number of EPSs are obtained from bacteria, and few have been reported from Archaea.¹⁶ The polysaccharides derived from marine bacteria differ in their biological activities, and chemical composition, and some of them show immunomodulatory and antiviral activities^{17,18}. In host cells, the absorption and penetration of viruses are interfered with by sulfated exopolysaccharides (EPS), inhibiting diverse retroviral reverse transcriptases. EPS-1 and EPS-2 were the new exopolysaccharides from two bacteria *Bacillus licheniformis* and *Geobacillus thermodenitrificans*, mainly found in the shallow marine hot spring of Vulcano Island, Italy.¹² Both the EPS at a concentration of ≤ 300 g/ml were non-toxic to PBMC's and WISH cells. There was a significant reduction in HSV-2 viral titer was observed by EPS-1 and EPS-2 at 200 and 300 g/ml concentrations showing the antiviral property of these exopolysaccharides. The cyanobacterium *Arthrospira platensis* produced polysaccharides containing spirulan-like molecules that inhibit the growth of human immunodeficiency virus type 1, human cytomegalovirus, herpes simplex virus type 1, and human herpesvirus type 6.¹⁹

Macrolactin A

Another antiviral compound isolated from marine bacteria is macrolactin A with a 24-member lactone ring, open chain acids connected to glucose-pyranosides. This compound protects T-lymphocyte from an HIV infection at 10 g/ml concentration and inhibits cancer cell proliferation.²⁰

Antiviral compounds from Fungi

Fungi occupy essential roles in terrestrial ecosystems as decomposers, drivers of the nutrient cycle in detritus environments, and parasites and symbionts.²¹ Due to their pathogenic and symbiotic roles, these organisms evolved to possess rich and promising novel bioactive natural products.²² Several of these metabolites possess antiviral properties against different influenza viral strains (Table 1). The rich antiviral activities of marine fungi-derived compounds against the

influenza virus can serve as baseline data for understanding the potential against a similar RNA virus, the SARS-CoV2 family.²³ Mangroves and corals host most of these fungal species, and the studies performed were only limited to screening, and only a few conducted experiments to establish mechanisms of action.

One of the mechanisms of action of marine fungi-derived antiviral compounds is the inactivation of viral replication. As shown in work on Enterovirus-71 (EV-71), compounds from *Stachybotrys* sp. were found to inhibit viral replication of the virus *in vitro*.²⁴ Another mechanism of collapsing the viral replication is inhibiting the integrase enzyme of HIV-1.²⁵ Moreover, Integric acid inhibits amalgamation reactions catalyzed by pre-integration compounds from HIV-1 infected cells. The same action was also noted in emerimidine A and B, where H1N1 viral replication was inhibited in Madin-Darby Canine Kidney (MDCK) cell lines.²⁶

Another mode of action is by destabilizing the viral membrane. In this way, these metabolites exert direct extracellular virucidal activity against HSV particles and thus inhibit HSV transmission.²⁷ In the influenza virus, a unique mechanism of action was noted from Stachyfin isolated from *Stachybotrys* sp.,²⁸ where the metabolite suppresses the first stage of H1N1 and H2N2 viral infection. The antiviral experiment was tested *in vivo* by oral administration of stachyfin with a solution of PEG.

Antiviral compounds from marine algae

The chemodiversity of algae offer a novel approach and can be recognized as a relevant source for developing a future natural antiviral drugs.^{45,46} *In vivo* or *in vitro* antiviral activity against a broad variety of viruses such as simian and human immune deficiency viruses, herpes viruses (HCMV, HSV-1, HSV-2), paramyxoviruses (RSV), togaviruses (semliki forest virus rhabdoviruses (VSV), sindbis virus) was shown by the compounds extracted from algae. From red algae extracts, polysaccharide fractions were isolated, inhibiting the growth of HSV and other viruses.⁴⁷ The polysaccharides extracted from marine algae show antiviral effects towards influenza B and mumps virus.⁴⁸ Sulfated polysaccharides were isolated from algae and other compounds which possess antiviral activity against enveloped viruses. Thus, interest in studying antiviral compounds isolated from marine algae increased (Table 2).

Table 1: Antiviral properties of compounds derived from fungi

Class	Species	Compound	Active against	Reference
	<i>Fusarium heterosporum</i>	Equisetin	HIV-1	25
Sordariomycetes	<i>Stachybotrys</i> sp.	Stachybotrysephenone B, Grisephenone A, and 3,6,8-Trihydroxy-1-methylxanthone	EV-71	24
	<i>Stachybotrys</i> sp.	Stachyfin	H1N1 and H2N2	28
	<i>Aspergillus terreus</i> SCSGAF0162	11a-dehydroxyisoterreulactone A, Arisugacin A, Isobutyrolactone II, and Aspernolide A	HSV	29
	<i>Aspergillus terreus</i> MXH-23	Butyrolactone Derivatives	H1N1	30
	<i>Aspergillus terreus</i> OUCMDZ-1925	Rubrolide S	H1N1	31
Eurotiomycetes	<i>Aspergillus terreus</i> SCSGAF0162	Asperterrestide A	H1N1 and H3N2	32
	<i>Aspergillus terreus</i> Gwq-48	Isoaspulvinone E, Aspulvinone E, and Pulvic acid	H1N1	33
	<i>Aspergillus sydowii</i> ZSDS1-F6	Diorcinol, Cordyol C, and (Z)-5-(Hydroxymethyl)-2-(6')-methylhept-2'-en-2'-yl)-phenol	Influenza virus	34

	<i>Aspergillus</i> sp. SCSIO 41501	Aspergillipeptide D	HSV-1	35
	<i>Aspergillus</i> sp. SCSIO XWS02F40	Asteltoxin E and F	H1N1 and H3N2	36
	<i>Aspergillus ochraceus</i> Jema1F17	6,9-dihydroxy-14- <i>p</i> -nitrobenzoylcinnamolide.	H3N2 and EV-71	37
	<i>Dichotomomyces cejpii</i> F31-1	Scequinadoline A	Dengue virus serotype-2	38
	<i>Emericella</i> sp.	Emerimidine A and B	H1N1	26
	<i>Penicillium chrysogenum</i> PJX-17	Sorbicatechol A and B	H1N1	39
	<i>Penicillium oxalicum</i> 0312F1	2-(4-hydroxybenzyl) quinazolin-4(3 <i>H</i>)-one and Methyl 4-hydroxyphenylacetate	Tobacco Mosaic Virus	40
	<i>Neosartorya fischeri</i> 1008F1	AGI-B4 and 3,4-dihydroxybenzoic acid	Tobacco Mosaic Virus	41
Leotiomycetes	<i>Scytalidium</i> sp.	Halovirs A–E	HSV	27
	<i>Phoma</i> sp.	Phomasetin	HIV	42
	<i>Cladosporium</i> sp.	Oxoglyantrypine, Norquinadoline A, Deoxynortryptoquivaline, Tryptoquivaline, and Quinadoline B	Influenza virus	43
Dothideomycetes	<i>Alternaria</i> sp. ZJ-2008003	Tetrahydroaltersolanol C and Alterporriol Q	Porcine Reproductive and Respiratory Syndrome Virus	44

Fucoidan

The sulfated polysaccharide (fucoidan) was isolated from *Fucus vesiculosus*, also known as brown seaweeds, which inhibits the human cytomegalovirus (HCMV),⁴⁹ DNA virus replication and herpes viruses (HSV-1, HSV-2). In the case of RNA viruses, fucoidan was also active against HIV-1, vesicular stomatitis virus (VSV), and Sinbis virus.⁵⁰ *In vitro* HIV RT was inhibited at a concentration of 50 g/ml by a noncarbohydrate component of fucoidan isolated from *F. vesiculosus*.⁵¹ The target cells pre-incubated with fucoidan protect them from HIV-1 infection⁵¹ since fucoidan holds low anticoagulation properties along with antiviral activity.⁵⁰

Tannins, Lectins, and Polysaccharides

The anti- HIV-1 activity was shown by algal products (tannins, lectins, and polysaccharides) derived from marine macroalgae.⁵²

Galactan sulfate

The polysaccharide named galactan sulfate (GS) was extracted from *Agardhiella tenera* also known as red seaweed. It indicates antiviral activity against HIV-1 and HIV-2 due to the presence of a polysaccharide called galactan sulfate (GS).⁵³ GS also inhibits other enveloped viruses such as arenaviruses, herpes viruses, and toga viruses by inhibiting virus adsorption and preventing expression of immediate early antigens of the virus.⁵³

Calcium spirulan

Many cyanobacteria species produced the anti-HIV active sulfoglycolipids in abundant amounts as it is a part of chloroplast membrane, whereas from marine blue-green alga,⁵⁴ *Arthrospira platensis*, a sulfated polysaccharide named calcium spirulan (Ca-SP) was isolated and it has potential antiviral activity against HIV-1 in MT-

4 cells.⁵⁵ Ca-SP was found to inhibit selectively the penetration of virus into host cells by retention of the molecular conformation and by chelation of calcium ions with the sulfate groups.

A1 and A2

The extracellular sulfated polysaccharides, A1 and A2, were extracted and purified from a marine microalga named *Cochlodinium polykrioides*.⁵⁵ These polysaccharides A1 and A2 show cytopathic effects by inhibiting the effects of RSV types A and B grown on Hep-2 cells and influenza virus types A and B grown on MDCK cells. In the case of MT-4 cells, an IC₅₀ value of 1.7g/ml was shown by A1 and A2 against HIV-1. In HMV-2 cells, the activity of A1 was against HSV-1, whereas the activity of A2 was against parainfluenza virus type 2.⁵⁵

p-KG03

Gyrodinium impudicum is a marine microalga that produces p-KG03, a sulfated polysaccharide with glucose units conjugated to sulfated groups and uronic acid. p-KG03 interacts with viral particles and prevents tumor cell proliferation and infection caused by encephalomyocarditis virus.⁵⁶

Diterpenes

From the marine alga *Dictyota menstrualis*, two diterpenes named Da-1 and AcDa-1 were isolated which inhibits the replication of the HIV-1 virus in the PM-1 cell line.⁵⁷ Da-1 (97%) and AcDa-1(70%) at 100M inhibit the production of viruses by inhibiting the RNA-dependent DNA polymerase activity of the viral reverse transcriptase enzyme. The proliferation and cell viability were not affected by these compounds.⁵⁷

Table 2: Antiviral properties of compounds derived from algae

Microalgal source	Type	Secondary metabolites	Bioactive compounds	Biological activities	References
<i>Griffithsia</i> sp.	Red algae	lectin	Griffithsin 12	Antiviral activity against SARS-CoV, hepatitis C Infection, HSV-2 vaginal infection	61
<i>Porphyridium</i> sp.	Red algae	sulfated polysaccharide (carrageenan)	xylose, glucose, galactose, and sulfate esters, hexuronic acids glucuronic acid and galacturonic acid	herpes simplex virus HSV1 and HSV-2, varicella zoster virus (VZV), retrovirus murine sarcoma virus (MuSV-124), MuSV/MuLV (murine leukemia virus), hepatitis B virus (HBV), viral haemorrhagic septicaemia virus (VHSV), African swine fever virus (ASFV), vesicular stomatitis virus (VSV), vaccinia virus VACV and VACV-GFP and ectromelia virus (ECTV)	62
<i>Schizymenia pacifica</i>	Red algae	polysaccharide	sulfated galactan	Antiviral activity against herpesviruses (HSV types 1 and 2)	63
<i>Enhalus</i> sp.	Sea grass	-	3-amino-3-deoxy-D-glucose, a new glucanase, and cyclic acylpeptides	Antibacterial activity against <i>Mycobacterium tuberculosis</i>	64
<i>Zosteraceae</i> family	Sea grass	polyphenol complex	rosmarinic acid, luteolin, and luteolin disulfate	Antiviral activity against Tick-Borne Encephalitis Virus, herpes, influenza, hepatitis, yellow fever	65
<i>Gracilaria corticata</i>	Marine red algae	terpenoid	4-acetoxy-2-hydroxy, 2, 6, 6-trimethyl cyclohexanone	antiviral activity against herpes simplex virus types 1 and 2	66
<i>Gracilaria lemaneiformis</i>	Red algae	sulfated polysaccharide	-	anti-influenza virus	67
<i>Dictyota bartaysiana</i> and <i>Turbinariade currence</i>	brown algae	sulphated polysaccharide	fucoidan	HIV (HIV-1 and HIV-2)	68
<i>Sargassum vulgare</i> .	brown seaweed	lipolytic enzymes lipid	1-lyso-2-DHA-phospholipids, CCAP 927/1 sulfoquinovosyldiac ylglycerols (SQDGs)	Antiviral	69

				Influenza Virus Neuraminidase	
				Inhibitory Activity porcine	
<i>Ecklonia stolonifera</i>	Brown Alga	sterols and phlorotannins	-	epidemic diarrhea coronavirus infection and hemagglutination	70
				acetylcholine esterase inhibitory activity	
<i>Spirulina</i>	Blue green algae	protein	Griffithsin (GRFT)	Antiviral activity against SARS coronavirus (SARS-CoV)	71
		sulfated polysaccharide	Cyanovirin-N (CV-N), Calcium	Antiviral activity against human immunodeficiency virus (HIV),	
		Alkaloids	spirulan (Ca-SP) –	hepatitis C virus (HCV), anti-	72
		Flavonoids	Antiviral 624	hepatitis activity Immuno-	
<i>Caulerpa racemosa</i>	Green algae	Phenols	polysaccharide	modulating antioxidant potential	
		Saponins			
		alkaloids,	seaweed extracts		
		phenolics,	against DENV	Antiviral activity against SARS-CoV	73,74
		flavonoids and	serotypes 1–4		
		steroids			

Griffithsin

A new type of lectin with potent antiviral activity named as griffithsin was extracted from red alga *Griffithsia* sp., which inactivates HIV and primary isolates of HIV-1 in a monosaccharide-dependent manner by binding viral glycoproteins.⁵⁸

Sea algal extract

Schizymenia pacifica is marine algae were purified to produce a sea algal extract (SAE) compound. The composition of this compound includes 3,6-anhydrogalactose (0.65%), galactose (73%) and sulfonate (20%). Research suggests that SAE inhibits in vitro replication of HIV and HIV RT and does not show any undesirable effects on cell growth, thus producing a significant role in the inhibition of reverse transcriptase (RT).⁵⁹

Naviculan

From deep-sea water in Toyama Bay, Japan, a diatom was collected termed *Navicula directa*, from which a sulfated polysaccharide naviculan was extracted, and this compound interferes in the early stages of viral replication by inhibiting HSV-1 and HSV-2.⁶⁰

Antiviral compounds from Sponges

Sponges (*Phylum Porifera*) are organisms that do not possess spines and are considered the most primitive multicellular animal.^{75,76} Due to the inability to move and the lack of physical defenses, they are often susceptible to marine predators. For this reason, these organisms can produce a myriad of chemical defenses to deter predators as part of their evolutionary adaptations.⁷ Moreover, a growing body of evidence suggests that the antiviral compounds derived from marine sponges may come from bacterial and fungal symbionts.⁷⁷

As shown in Table 3, a compound from *Axinella corrugata* showed effective inhibition of SARS-CoV viral replication in Vero cells, and this activity was found to be non-cytotoxic.⁷⁸ Moreover, due to the limited amount extracted from this compound, it was hypothesized that this is of microbial origin. Pseudothionamide C and D, isolated from the sponge *Theonellaswinhoei*, were found to form covalent bonds with Cys145 residue of SARS-CoV-2 3CL^{pro} through a docking study.⁷⁹ The majority of the antiviral studies done on sponge-derived compounds were on HIV. The inhibition of viral replication was believed to be the reason for their antiviral properties. Some other suggested targets of

these antiviral compounds are viral adsorption and viral penetration. One example is the study performed on 4-methylaptamine from *Aaptos aaptos* where results showed that the antiviral properties could be partially explained by the inhibition of viral penetration in live cells, while viral adsorption was rejected as a possible mechanism of action.⁸⁰ Similarly, avarol from *Dysidea avara* was noted to block the expression of p24 and p17 gag proteins, thereby inhibiting viral replication.⁸¹ A similar mechanism of action was noted from an antiviral compound isolated from *Petromica citrina* where virus attachment and penetration to Vero cells were inhibited.⁸²

Antiviral compounds from Echinoderms

Echinoderms inhabit the benthic region, which is considered useful in medical research due to its richness in species and chemical biodiversity^{100,101}. One particular importance in medicine of these organisms in this region is their substantial potential lead source of antiviral compounds.¹⁰² Although no experimental and docking study was conducted on echinoderm-derived compounds against the family of coronaviruses, rich data on antiviral activities against other viral strains can be used as a benchmark for future studies. This signifies the importance of understanding their ethnopharmacological value other than the well-established ecological significance of these species.¹⁰³ Most of the antiviral compounds extracted from echinoderms are active against HSV, as shown in Table 4.

The mechanism of action of these compounds have been theorized to be a result of the inactivation of viral particles.¹⁰⁴ In sea cucumbers, the mechanism believed to be due to the presence of sulfated polysaccharides that possess anti-adsorption activity against Herpes Simplex Virus Type 1 (HSV-1). This mechanism has been well documented in other marine organisms.^{56,105} The action of polysaccharides against this virus was also documented in another species of sea cucumber, where an acid mucopolysaccharide showed to fight against HSV-1¹⁰⁶. Similarly, virucidal effects against HSV-1 were also noted from the sulfated carbohydrate chain in a sea cucumber.¹⁰⁷ This further indicates that naturally occurring saponins possess inhibitory effects against HSV by interfering with the early step in the viral replicative cycle or by a direct virucidal effect. A similar mechanism of action was noted in the HIV-1 virus, where the active compound was noted to inhibit viral replication.

Table 3: Antiviral properties of compounds derived from sponges

Class	Species	Compound	Active against	Reference	
Demospongiae	<i>Aaptos aaptos</i>	4-methylaaptamine (alkaloid)	HSV-1	80	
	<i>Theonella</i> sp.	Papaumides A to D (cyclic depsipeptides)	HIV-1	83	
	<i>Tectitethya crypta</i>	Ara-A (Nucleoside)	HSV-1, HSV-2, and VCV	84	
	<i>Dysideaavara</i>	Avarol (Sesquiterpene hydroquinone)	HIV-1 and Human T-lymphotropic retrovirus	85	
	<i>Xestospongia</i> sp. and an unidentified Haplosclerida species	Haplosamates A and B (Sulfamated sterol)	HIV-1	86	
	<i>Halicortex</i> sp.	Dragmacidin F	HIV-1	87	
	<i>Hamigeratarangaensis</i>	Hamigeran B	Herpes and polio virus	88	
	<i>Mycale</i> sp.	Mycalamide A and B	A59 coronavirus and HSV-1	89	
	<i>Siliquariaspongia mirabilis</i>	Mirabamide A, C, and D	HIV-1	90	
	<i>Stylissa carteri</i>	Oroidin	HIV-1	91	
	<i>Erylus discophorus</i>	Sulfated polysaccharide	HIV-1	92	
	<i>Acanthostrongylophora</i> sp.	Manadomanzamines A and B	HIV-1 and AIDS opportunistic fungal infections	93	
	<i>Hyrtios</i> sp. and <i>Haliclona</i> sp.	1304KO-327 and 1304KO-328	Rotavirus	94	
	<i>Carteriospongia</i> sp.	Hennoxazoles A	HSV-1	95	
	<i>Petromicacitrina</i>	Halistanol sulfate C	HSV-1	82	
	<i>Spongia</i> sp.		Bromopyrrole metabolites	HSV-1	96
			Isospongiadol	HSV-1	97,92
			Sipholenol A, Neviotine A*, Sipholenol L*	Hepatitis A virus, HSV-1	98
	Calcarea	<i>Pericharaxheteroraphis</i>	Imidazole Alkaloids	H1N1	99

Table 4: Antiviral properties of compounds derived from echinoderms

Class	Species	Component	Active against	Reference
Holothuroidea	<i>Holothuria</i> sp.	Crude extract	HSV-1	104
	<i>Sticophus japonicus</i>	Acid Mucopolysaccharide	HSV-1	106
	<i>Staurocucumis liouvillei</i>	Liouvilloside A	HSV-1	107
	<i>Cucumaria japonica</i>	Cucumariaxanthins C	Eipstein-Barr Virus	108
	<i>Cucumaria frondosa</i>	Extracts from aquapharyngeal bulb	HSV-1	109
	<i>Thelenotia anana</i>	Fucosylated chondroitin sulfate	HIV-1	110
Ophiuroidea	<i>Ophioplocus januarii</i>	Sulfated polyhydroxysteroids	HSV-1, Junín virus, respiratory syncytial virus, and polio virus	111
	<i>Astrotoma agassizii</i>	Sulfated Polyhydroxysteroids	HSV-2, Junín virus, and polio virus type 3	112

	<i>Asterina pectinifera</i>	Polyhydroxysteroids and Asterosaponins	HSV-1	113
Asteroidea	<i>Certonardoa semiregularis</i>	Certonardoside A, I, and J	HSV-1*, HIV*, Coxsackievirus*, encephalomyocarditis virus*, and vesicular stomatitis virus*	114
	<i>Acanthaster planci</i>	Phospholipase A2	HIV	115
	<i>Tripneustes depressus</i>	Coelemic fluid	SHV-1 and rabies	116
Echinoidea	Sea Urchins (<i>i.e.</i> , <i>Paracentrotus lividus</i> and <i>Psammechinus miliaris</i>)	Echinochrome A	HSV-1 and TBEV	117
Crinoidea	<i>Gymnocrinus richeri</i>	Gymnochrome B and D and Isogymnochrome D	Dengue virus	118

*weak antiviral activity

This mechanism is believed to be due to sulfated polysaccharides that possess anti-adsorption activity. Similarly, the action mechanism of an acid polysaccharide against the virus was also documented in another species of sea cucumber.^{106,107} This highlights the inhibitory effects of naturally occurring saponins against viral strains by interfering with the early step in the viral replication or by a direct virucidal effect.

Starfish have also attracted researchers as a fascinating source of bioactive marine natural products.¹¹⁹ The antiviral properties were believed to be due to sulfated sterol compounds, which possess activity against human immunodeficiency virus derived from these marine invertebrates.¹²⁰ Moreover, the antiviral properties of starfish-derived compounds were suggested to be due to the bioactivity of the hydroxyl and sulfate groups and that the sugar unit attached to the compound has a significant effect on its activity.¹¹⁵ Phospholipase from *Acanthaster planci* crude venom was also found to reduce the *in vivo* HIV infection rate and HIV-specific RNA in PBMC culture by inhibiting viral replication.¹¹⁵ This suggests that the antiviral properties are not only limited to the inactivation of viral particles but also by arresting RNA replication.

Similarly, brittle stars and sea urchins possess compounds with antiviral properties. This activity is believed to be due to the sulfate group, critical to inhibiting the virus.¹¹² This relationship between the structure of sulfate groups and their bioactivity is not surprising since a number of sulfated steroids have been reported to possess a myriad of biological activities.¹²¹ Moreover, thermostable antiviral compounds were also isolated from sea urchins, which could be a promising source of antiviral drugs.¹¹⁶

Future Directions

The first antiviral drug "vidarabine" approved by US Food and Drug Administration (FDA), 1976 derived from the natural arabinonucleosides. The SARS-CoV-2 main protease (M^{pro}) is identified as a pharmacological target for discovering and designing inhibitors such as SARS-CoV-2. To date, 17 potential SARS-CoV-2 M^{pro}inhibitors have been identified among marine natural products. Among them, Gentile et al.⁷⁹ found compounds **7**(8,8'-Bieckol), **10**(6,6'-Bieckol), and **11**(Dieckol) are as the most potent inhibitor against the SARS-CoV-2 due to strong affinity for main protease (M^{pro}). These compounds belong to the family of phlorotannins, isolated in the brown algae *Ecklonia cava*. Pseudotheonamide D (**12**) and pseudotheonamide C (**17**) have been isolated from the marine sponge *Theonella swinhoei* and have shown good inhibitory activity on the serine protease.¹²² Currently, Khan et al.¹²³ investigated five marine compounds, namely C-1, C-2, C-3, C-4, and C-5 to target SARS-CoV-2 main protease (M^{pro}) (PDB ID 6MO3) and showed good binding affinity to the active site of the protease. The other docking study identified Apigenin- 7-O-neohesperidoside, Luteolin-7-rutinoside, and Resinoside, belonging to the class of flavonoids, exhibit high binding interaction.

Compared to synthetic compounds, the success ratio for natural compounds from marine resources is very high, and their potential in clinical trials is very promising.¹²⁴ Almost all marine organisms (e.g., bacteria, algae, sponges, fungi, corals, ascidians, etc.) contain natural products with potent biological activity that have been investigated for their antiviral activity. However, no study is available¹²⁵ on the clinical trials of such antiviral compounds extracted from marine resources specifically dedicated to COVID-19 treatment. Therefore, it is also an unexplored area for the researcher to explore the antiviral compound from marine resources and emphasize its impact on coronavirus infection. This highlights that future researches may be conducted to screen out identified compounds from marine organisms against coronavirus. Docking studies and other pharmacological and bioactive assays are important in assessing, elucidating, and identifying the mode of action, mechanism, and inactivation of viruses.

Conclusion

The previous SARS epidemic, Ebola, AIDS, and the current Covid-19 pandemic have created the task of finding a solution to counteract viral entry and pathogenesis. The marine natural products are the reservoir of largely unexplored structural and chemical diverse compounds and also have high growth rates and biomass productivity with other natural resources. In this review, we report a large number of compounds in almost all marine organisms (e.g., bacteria, algae, sponges, fungi, echinoderm, etc.) display *in vitro* and *in vivo* efficiency to discover drugs against human viruses, including SARS, Ebola, influenza, AIDS, and herpes. The marine resources have chemo diversity, which may serve as potential resources to develop new antiviral drugs and pave the way to develop new drugs against the new COVID-19 infections. Although, more *in vivo* and clinical studies are needed to conduct in search of a new, potential drug against SARS-CoV-2. As such, these descriptions of the mode of actions, mechanisms, pharmacology, bioactivity of different compounds isolated from marine organisms can be used in further screening for lead compounds with bioactivity against coronavirus.

Conflict of Interest

The authors declare no conflict of interest.

Authors' Declaration

The authors hereby declare that the work presented in this article is original and that any liability for claims relating to the content of this article will be borne by them.

Acknowledgments

AMPW was supported by the Department of Science and Technology, India, and the Federation of Indian Chambers of Commerce and Industry under the ASEAN-India Research Training Fellowship (AIRTF) Grant RTF/2019/000048. RNK expresses his thanks to Head and Coordinator, CAS in Botany BHU; to Coordinator, ISLS and IoE, BHU, Varanasi, India for their technical and minor financial supports. The authors would also like to acknowledge the funding granted by the National Research Council of the Philippines.

References

1. Arrazola J, Masiello MM, Joshi S, Dominguez AE, Poel A, Wilkie CM, Bressler JM, McLaughlin J, Kraszewski J, Komatsu KK, Peterson Pompa X, Jespersen M, Richardson G, Lehnertz N, LeMaster P, Rust B, Keyser Metobo A, Doman B, Casey D, Kumar J, Rowell AL, Miller TK, Mannell M, Naqvi O, Wendelboe AM, Leman R, Clayton JL, Barbeau B, Rice SK, Warren-Mears V, Echo-Hawk A, Apostolou A, Landen M. COVID-19 Mortality Among American Indian and Alaska Native Persons — 14 States, January–June 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(49):1853-1856.
2. Geahchan S, Ehrlich H, Rahman MA. The anti-viral applications of marine resources for COVID-19 treatment: An overview. *Mar Drugs.* 2021;19(8):409-422.
3. Sun T-T, Zhu H-J, Cao F. Marine Natural Products as a Source of Drug Leads against Respiratory Viruses: Structural and Bioactive Diversity. *Curr Med Chem.* 2020;28(18):3568-3594.
4. Chakravarti R, Singh R, Ghosh A, Dey D, Sharma P, Velayutham R, Roy S, Ghosh D. A review on potential of natural products in the management of COVID-19. *RSC Adv.* 2021;11(27):16711-16735.
5. Taglialatela-Scafati O. New Hopes for Drugs against COVID-19 Come from the Sea. *Mar Drugs.* 2021;19(21):104-105.
6. Manzo E. Synthesis of marine natural products and molecules inspired by marine substances. *Mar Drugs.* 2021;19(4):208-210.
7. Walag AMP. Bioactivities of Extracts from Different Marine Organisms around the World (2000 to Present). *Biomed J Sci Tech Res.* 2017;1(7):1-3.
8. Sigwart JD, Blasiak R, Jaspars M, Jouffray JB, Tasdemir D. Unlocking the potential of marine biodiscovery. *Nat Prod Rep.* 2021;38(7):1235-1242.
9. Zaporozhets TS, Besednova NN. Biologically active compounds from marine organisms in the strategies for combating coronaviruses. *AIMS Microbiol.* 2020;6(4):470-494.
10. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. *Nat Rev Drug Discov.* 2009;8(1):69-85.
11. Putz A, Proksch P. Chemical Defence in Marine Ecosystems. in Wink, M, editor. *Functions and Biotechnology of Plant Secondary Metabolites* 2nd Ed. 2018. p. 162-131.
12. Arena A, Gugliandolo C, Stassi G, Pavone B, Iannello D, Bisignano G, Maugeri TL. An exopolysaccharide produced by *Geobacillus thermodenitrificans* strain B3-72: Antiviral activity on immunocompetent cells. *Immunol Lett.* 2009;123(2):132-137.
13. Vincent P, Pignet P, Talmont F, Bozzi L, Fournet B, Guezennec J, Jeanthon C, Prieur D. Production and characterization of an exopolysaccharide excreted by a deep-sea hydrothermal vent bacterium isolated from the polychaete annelid *Alvinella pompejana*. *Appl Environ Microbiol.* 1994;60(11):4134-4141.
14. Ahmad AS, Matsuda M, Shigeta S, Okutani K. Revelation of antiviral activities by artificial sulfation of a glycosaminoglycan from a marine *Pseudomonas*. *Marine Biotechnology.* 1999;1(1):102-106.
15. Rinker KD, Kelly RM. Effect of carbon and nitrogen sources on growth dynamics and exopolysaccharide production for the hyperthermophilic archaeon *Thermococcus litoralis* and bacterium *Thermotoga maritima*. *Biotechnol Bioeng.* 2000;69(5):537-547.
16. Poli A, Anzelmo G, Nicolaus B. Bacterial exopolysaccharides from extreme marine habitats: Production, characterization and biological activities. *Mar Drugs.* 2010. Doi: 10.3390/md8061779.
17. Nichols CM, Lardière SG, Bowman JP, Nichols PD, Gibson JAE, Guézennec J. Chemical characterization of exopolysaccharides from Antarctic marine bacteria. *Microb Ecol.* 2005;49(4):578-589.
18. Laurienzo P. Marine polysaccharides in pharmaceutical applications: An overview. *Mar Drugs.* 2010;8(9):2435-2465.
19. Rechter S, König T, Auerochs S, Thulke S, Walter H, Dörnenburg H, Walter C, Marschall M. Antiviral activity of Arthrospira-derived spirulan-like substances. *Antiviral Res.* 2006;72(3):197-206.
20. Gustafson K, Roman M, Fenical W. The Macrolactins, a Novel Class of Antiviral and Cytotoxic Macrolides from a Deep-Sea Marine Bacterium. *J Am Chem Soc.* 1989;111(19):7519-7524.
21. Wang HN, Sun SS, Liu MZ, Yan MC, Liu YF, Zhu Z, Zhang Z. Natural bioactive compounds from marine fungi (2017–2020). *J Asian Nat Prod Res.* 2022;24(3):203-230.
22. Takahashi JA, Barbosa BVR, Lima MTNS, Cardoso PG, Contigli C, Pimenta LPS. Antiviral fungal metabolites and some insights into their contribution to the current COVID-19 pandemic. *Bioorg Med Chem.* 2021; 46:116366.
23. Srivastav AK, Jaiswal J, Kumar U. In silico bioprospecting of antiviral compounds from marine fungi and mushroom for rapid development of nutraceuticals against SARS-CoV-2. *J Biomol Struct Dyn.* 2021:1-12.
24. Qin C, Lin X, Lu X, Wan J, Zhou X, Liao S, Tu Z, Xu S, Liu Y. Sesquiterpenoids and xanthenes derivatives produced by sponge-derived fungus *Stachybotry* sp. HH1 ZSDS1F1-2. *J of Antibio.* 2015;68(2):121-125.
25. Singh SB, Zink DL, Goetz MA, Dombrowski AW, Polishook JD, Hazuda DJ. Equisetin and a novel opposite stereochemical homolog phomasetin, two fungal metabolites as inhibitors of HIV-1 integrase. *Tetrahedron Lett.* 1998;39(16):2243-2246.
26. Zhang G, Sun S, Zhu T, Lin Z, Gu J, Li D, Gu Q. Antiviral isoindolone derivatives from an endophytic fungus *Emericella* sp. associated with *Aegiceras corniculatum*. *Phytochemistry.* 2011;72(11-12):1436-1442.
27. Rowley D, Kelly S, Kauffman C, Jensen P, Fenical W. Halovirs A–E, new antiviral agents from a marine-Derived fungus of the genus *Scytalidium*. *Bioorg Med Chem.* 2003;11(19P):4263–74.
28. Yagi S, Ono J, Yoshimoto J, Sugita KI, Hattori N, Fujioka T, Fujiwara T, Sugimoto H, Hirano K, Hashimoto N. Development of anti-influenza virus drugs I: Improvement of oral absorption and in vivo anti-influenza activity of Stachyflin and its derivatives. *Pharm Res.* 1999;16(7):1041–6.
29. Nong XH, Wang YF, Zhang XY, Zhou MP, Xu XY, Qi SH. Territrem and butyrolactone derivatives from a marine-derived fungus *Aspergillus terreus*. *Mar Drugs.* 2014;12(12):6113-6124.
30. Ma X, Zhu T, Gu Q, Xi R, Wang W, Li D. Structures and antiviral activities of butyrolactone derivatives isolated from *Aspergillus terreus* MXH-23. *J of Ocean Uni of China.* 2014;13(6):1067-1070.
31. Zhu T, Chen Z, Liu P, Wang Y, Xin Z, Zhu W. New rubrolides from the marine-derived fungus *Aspergillus*

- terreus* OUCMDZ-1925. J Antibiot (Tokyo). 2014;67(4):315–8.
32. He F, Bao J, Zhang X-Y, Tu Z-C, Shi Y-M, Qi S-H. Asperterrestide A, a Cytotoxic Cyclic Tetrapeptide from the Marine-Derived Fungus *Aspergillus terreus* SCSGAF0162. J Nat Prod. 2013;76(6):1182–6.
 33. Gao H, Guo W, Wang Q, Zhang L, Zhu M, Zhu T, Gu Q, Wang W, Li D. Aspulvinones from a mangrove rhizosphere soil-derived fungus *Aspergillus terreus* Gwq-48 with anti-influenza A viral (H1N1) activity. Bioorg Med Chem Lett. 2013;23(6):1776–8.
 34. Wang JF, Lin XP, Qin C, Liao SR, Wan JT, Zhang TY, Liu J, Fredimoses M, Chen H, Yang B, Zhou XF, Yang XW, Tu ZC, Liu YH. Antimicrobial and antiviral sesquiterpenoids from sponge-associated fungus, *Aspergillus sydowii* ZSDS1-F6. J Antibiot. 2014;67(8):581-583.
 35. Ma X, Nong X-H, Ren Z, Wang J, Liang X, Wang L, Qi S-H. Antiviral peptides from marine gorgonian-derived fungus *Aspergillus* sp. SCSIO 41501. Tetrahedron Lett. 2017;58(12):1151–5.
 36. Tian YQ, Lin XP, Wang Z, Zhou XF, Qin XC, Kaliyaperumal K, Zhang TY, Tu ZC, Liu Y. Asteltoxins with antiviral activities from the marine sponge-Derived fungus *Aspergillus* sp. SCSIO xws02f40. Molecules. 2016;21(1):34-43.
 37. Fang W, Lin X, Zhou X, Wan J, Lu X, Yang B, Ai W, Lin J, Zhang T, Tu Z, Liu Y. Cytotoxic and antiviral nitrobenzoyl sesquiterpenoids from the marine-derived fungus *Aspergillus ochraceus* Jcm1F17. Med Chem Commun. 2014;5(6):701–5.
 38. Wu D-L, Li H-J, Smith D, Jaratsittisin J, Xia-Ke-Er X-F-K-T, Ma W-Z, Guo Y-W, Dong J, Shen J, Yang D-P, Lan W-J. Polyketides and Alkaloids from the Marine-Derived Fungus *Dichotomomyces cejpilii* F31-1 and the Antiviral Activity of Scequinadoline A against Dengue Virus. Mar Drugs. 2018;16(7):229-238.
 39. Peng J, Zhang X, Du L, Wang W, Zhu T, Gu Q, Li D. Sorbicatechols A and B, Antiviral Sorbicillinoids from the Marine-Derived Fungus *Penicillium chrysogenum* PJX-17. J Nat Prod. 2014;77(2):424–8.
 40. Shen S, Li W, Wang J. A novel and other bioactive secondary metabolites from a marine fungus *Penicillium oxalicum* 0312F 1. Nat Prod Res. 2013;27(24):2286-2291.
 41. Tan QW, Ouyang MA, Shen S, Li W. Bioactive metabolites from a marine-derived strain of the fungus *Neosartorya fischeri*. Nat Prod Res. 2012;26(15):1402-1407.
 42. Singh SB, Zink D, Polishhook J, Valentino D, Shafiee A, Silverman K, Felock P, Teran A, Vilella D, Hazuda DJ, Lingham RB. Structure and absolute stereochemistry of HIV-1 integrase inhibitor integric acid. A novel eremophilane sesquiterpenoid produced by a *Xylaria* sp. Tetrahedron Lett. 1999;40(50):8775–9.
 43. Peng J, Lin T, Wang W, Xin Z, Zhu T, Gu Q, Li D. Antiviral alkaloids produced by the mangrove-derived fungus *Cladosporium* sp. PJX-41. J Nat Prod. 2013;76(6):1133-1140.
 44. Zheng C-J, Shao C-L, Guo Z-Y, Chen J-F, Deng D-S, Yang K-L, Chen Y-Y, Fu X-M, She Z-G, Lin Y-C, Wang C-Y. Bioactive Hydroanthraquinones and Anthraquinone Dimers from a Soft Coral-Derived *Alternaria* sp. Fungus. J Nat Prod. 2012;75(2):189–97.
 45. Sami N, Ahmad R, Fatma T. Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2. Biomed J. 2021;44(1):54-62.
 46. Alam MA, Parra-Saldivar R, Bilal M, Afroze CA, Ahmed MN, Iqbal HMN, Xu J. Algae-derived bioactive molecules for the potential treatment of sars-cov-2. Molecules. 2021; 26(8):2134-2149.
 47. Richards JT, Kern ER, Glasgow LA, Overall JC, Deign EF, Hatch MT. Antiviral activity of extracts from marine algae. Antimicrob Agents Chemother. 1978;14(1):24-30.
 48. Gerber P, Dutcher JD, Adams E v., Sherman JH. Protective Effect of Seaweed Extracts for Chicken Embryos Infected with Influenza B or Mumps Virus. Pro Soc Experim Bio Med. 1958;99(3):590-593.
 49. Béress A, Wassermann O, Bruhn T, Béress L, Kraiselburd EN, Gonzalez LV, de Motta GE, Chavez PI. A new procedure for the isolation of anti-HIV compounds (polysaccharides and polyphenols) from the marine alga *Fucus vesiculosus*. J Nat Prod. 1993;56(4):478-488.
 50. Baba M, Snoeck R, Pauwels R, de Clercq E. Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother. 1988;32(11):1742-1745.
 51. Moen LK, Clark GF. A novel reverse transcriptase inhibitor from *Fucus vesiculosus*. Int Conf AIDS, 1993; 9(10):145-161.
 52. Kim SK, Karadeniz F. Anti-HIV activity of extracts and compounds from marine algae. Adv in Food Nut Res, 2011;64:255-265.
 53. Witvrouw M. Antiviral activity of a sulfated polysaccharide extracted from the red seaweed *Aghardheilla tenera* against human immunodeficiency virus and other enveloped viruses. Antiviral Chem Chemother. 1994; 5:2303–997.
 54. Reshef V, Mizrahi E, Marezki T, Silberstein C, Loya S, Hizi A, Carmeli S. New acylated sulfoglycolipids and digalactolipids and related known glycolipids from cyanobacteria with a potential to inhibit the reverse transcriptase of HIV-1. J Nat Prod. 1997;60(12):1251-1260.
 55. Hayashi T, Hayashi K, Maeda M, Kojima I. Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga *Spirulina platensis*. J Nat Prod. 1996;59(1):83-87.
 56. Kim M, Yim JH, Kim SY, Kim HS, Lee WG, Kim SJ, Kang PS, Lee CK. In vitro inhibition of influenza A virus infection by marine microalga-derived sulfated polysaccharide p-KG03. Antiviral Res. 2012;93(2):253-259.
 57. Pereira HS, Leão-Ferreira LR, Moussatché N, Teixeira VL, Cavalcanti DN, Costa LJ, Diaz R, Frugulhetti ICPP. Antiviral activity of diterpenes isolated from the Brazilian marine alga *Dictyota menstualis* against human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2004; 64(1):69-76.
 58. Mori T, O'Keefe BR, Sowder RC, Bringans S, Gardella R, Berg S, Cochran P, Turpin JA, Buckheit RW, McMahon JB, Boyd MR. Isolation and characterization of Griffithsin, a novel HIV-inactivating protein, from the red alga *Griffithsia* sp. J Bio Chem. 2005; 280(10):9345-9353.
 59. Nakashima H, Kido Y, Kobayashi N, Motoki Y, Neushul M, Yamamoto N. Antiretroviral activity in a marine red alga: reverse transcriptase inhibition by an aqueous extract of *Schizymenia pacifica*. J Cancer Res Clin Oncol. 1987; 113(5):413-416.
 60. Lee JB, Hayashi K, Hirata M, Kuroda E, Suzuki E, Kubo Y, Hayashi T. Antiviral sulfated polysaccharide from *Navicula directa*, a diatom collected from deep-sea water in Toyama Bay. Biol Pharm Bull. 2006; 29(10):2135-2139.
 61. O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PKS, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB. Broad-Spectrum In Vitro Activity and In Vivo Efficacy of the Antiviral Protein Griffithsin against Emerging Viruses of the Family Coronaviridae. J Virol. 2010; 84(5):2511-2521.
 62. Gaikwad M, Pawar Y, Nagle V, Santanu D. Marine red alga *Porphyridium* sp. as a source of sulfated polysaccharides (SPs) for combating against COVID-19. Preprints (Basel). 2020;(April).
 63. Matsuhiro B, Conte AF, Damonte EB, Kolender AA, Matulewicz MC, Mejías EG, Pujol CA, Zúñiga EA. Structural analysis and antiviral activity of a sulfated galactan

- from the red seaweed *Schizymenia binderi* (Gigartinales, Rhodophyta). Carbohydr Res. 2005; 340(15):2392-2402.
64. Sulistiyani, Wahjono H, Radjasa OK, Sabdono A, Khoeri MM, Karyana E. Antimycobacterial Activities from Seagrass *Enhalus* sp. Associated Bacteria Against Multi Drug Resistance Tuberculosis (MDR TB) Bacteria. Procedia Environ Sci. 2015; 23:253-259.
 65. Krylova N v., Leonova GN, Maystrovskaya OS, Popov AM, Artyukov AA. Mechanisms of Antiviral Activity of the Polyphenol Complex from Seagrass of the Zosteraceae Family against Tick-Borne Encephalitis Virus. Bull Exp Biol Med. 2018; 165(1):61-63.
 66. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: A systematic review. AIDS. 2012; 26(16):2059-2067.
 67. Chen MZ, Xie HG, Yang LW, Liao ZH, Yu J. In vitro anti-influenza virus activities of sulfated polysaccharide fractions from *Gracilaria lemaneiformis*. Virol Sin. 2010; 25(5):341-351.
 68. Sanniyasi E, Venkatasubramanian G, Anbalagan MM, Raj PP, Gopal RK. In vitro anti-HIV-1 activity of the bioactive compound extracted and purified from two different marine macroalgae (seaweeds) (*Dictyota bartayesiana* J.V. Lamouroux and *Turbinaria decurrens* Bory). Sci Rep. 2019;9(1):12185.
 69. Plouguerné E, de Souza LM, Sasaki GL, Cavalcanti JF, Romanos MTV, da Gama BAP, Pereira RC, Barreto-Bergter E. Antiviral sulfoquinovosyldiacylglycerols (SQDGs) from the Brazilian brown seaweed *Sargassum vulgare*. Mar Drugs. 2013; 11(11):4628-4640.
 70. Ryu YB, Jeong HJ, Yoon SY, Park JY, Kim YM, Park SJ, Rho MC, Kim SJ, Lee WS. Influenza virus neuraminidase inhibitory activity of phlorotannins from the edible brown alga *Ecklonia cava*. J Agric Food Chem. 2011; 59(12):6467-6473.
 71. George J. Young COVID-19 Stroke Victims; Alzheimer's Seaweed Drug; Parkinson's Med OK'd. MEDPAGE TODAY.
 72. Nagulendran K, Kavitha N. Antiviral and Immune Modulating Role of Super Food Spirulina and Covid-19. I J of Trend in Sci R and D. 2020; 4(4):621-6.
 73. Lin LT, Hsu WC, Lin CC. Antiviral natural products and herbal medicines. J Tradit Complement Med. 2014; 4(1):24-35.
 74. Srivastava N, Saurav K, Mohanasrinivasan V, Kannabiran K, Singh M. Antibacterial potential of macroalgae collected from the Madappam coast, India. British Journal of Pharmacology and Toxicology. 2010; 1(2):72-6.
 75. Anjum K, Abbas SQ, Shah SAA, Akhter N, Batool S, Hassan SSU. Marine sponges as a drug treasure. Biomol Ther (Seoul). 2016; 24(4):347-362.
 76. Walag AMP. Understanding the World of benthos: an introduction to benthology. in: Godson PS, Vincent SGT, Krishnakumar S, editors. Ecology and Biodiversity of Benthos. 1st ed. 2022; 1-18.
 77. Ridley CP, Bergquist PR, Harper MK, Faulkner DJ, Hooper JNA, Haygood MG. Speciation and biosynthetic variation in four dictyoceratid sponges and their cyanobacterial symbiont, *Oscillatoria spongeliae*. Chem Biol. 2005; 12(3):397-406.
 78. de Lira SP, Selegim MHR, Williams DE, Marion F, Hamill P, Jean F, Andersen RJ, Hajdu E, Berlinck RGS. A SARS-coronavirus 3CL protease inhibitor isolated from the marine sponge *Axinella* cf. *corrugata*: Structure elucidation and synthesis. J Braz Chem Soc. 2007; 18(2):440-443.
 79. Gentile D, Patamia V, Scala A, Sciortino MT, Piperno A, Rescifina A. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study. Mar Drugs. 2020; 18(4):225.
 80. Souza T, Abrantes J, Epifanio R, Fontes C, Frugulhetti I. The Alkaloid 4-Methylaaptamine Isolated from the Sponge *Aaptos aaptos* Impairs Herpes simplex Virus Type 1 Penetration and Immediate-Early Protein Synthesis. Planta Med. 2007; 73(3):200-5.
 81. Sagar S, Kaur M, Minneman KP. Antiviral lead compounds from marine sponges. Mar Drugs. 2010; 8(10):2619-2638.
 82. da Rosa Guimarães T, Quiroz C, Rigotto C, de Oliveira S, de Almeida M, Bianco É, Moritz M, Carraro J, Palermo J, Cabrera G, Schenkel E, Reginatto F, Simões C. Anti HSV-1 Activity of Halistanol Sulfate and Halistanol Sulfate C Isolated from Brazilian Marine Sponge *Petromica citrina* (Demospongiae). Mar Drugs. 2013; 11(11):4176-92.
 83. Ford PW, Gustafson KR, McKee TC, Shigematsu N, Maurizi LK, Pannell LK, Williams DE, Dilip de Silva E, Lassota P, Allen TM, van Soest R, Andersen RJ, Boyd MR. Papuamides A-D, HIV-Inhibitory and Cytotoxic Depsipeptides from the Sponges *Theonella mirabilis* and *Theonella swinhoei* Collected in Papua New Guinea. J Am Chem Soc. 1999; 121(25):5899-909.
 84. Faulkner DJ. Marine natural products. Nat Prod Rep. 2002; 19(1):1-48.
 85. Müller WEG, Sobel C, Diehl-Seifert B, Maidhof A, Schröder HC. Influence of the antileukemic and anti-human immunodeficiency virus agent avarol on selected immune responses *in vitro* and *in vivo*. Biochem Pharmacol. 1987; 36(9):1489-1494.
 86. Qureshi A, Faulkner DJ. Haplosamates A and B: New steroidal sulfamate esters from two haploselerid sponges. Tetrahedron. 1999; 55(28):8323-8330.
 87. Cutignano A, Bifulco G, Bruno I, Casapullo A, Gomez-Paloma L, Riccio R. Dragmacidin F: A new antiviral bromoindole alkaloid from the mediterranean sponge *Halicortex* sp. Tetrahedron. 2000; 56(23):3743-3748.
 88. Wellington KD, Cambie RC, Rutledge PS, Bergquist PR. Chemistry of Sponges. 19. Novel Bioactive Metabolites from *Hamigera tarangaensis*. J Nat Prod. 2000; 63(1):79-85.
 89. Perry NB, Blunt JW, Munro MHG, Thompson AM. Antiviral and Antitumor Agents from a New Zealand Sponge, *Mycale* sp. 2. Structures and Solution Conformations of Mycalamides A and B. Journal of Organic Chemistry. 1990; 55(1):223-227.
 90. Plaza A, Gustchina E, Baker HL, Kelly M, Bewley CA. Mirabamides A-D, Depsipeptides from the Sponge *Siliquariaspongia mirabilis* That Inhibit HIV-1 Fusion. J Nat Prod. 2007; 70(11):1753-60.
 91. O'Rourke A, Kremb S, Bader TM, Helfer M, Schmitt-Kopplin P, Gerwick WH, Brack-Werner R, Voolstra CR. Alkaloids from the sponge *Stylissa carteri* present prospective scaffolds for the inhibition of human immunodeficiency virus 1 (HIV-1). Mar Drugs. 2016; 14(2):28.
 92. Esteves AIS, Nicolai M, Humanes M, Goncalves J. Sulfated Polysaccharides in Marine Sponges: Extraction Methods and Anti-HIV Activity. Mar Drugs. 2011; 9(1):139-53.
 93. Peng J, Hu JF, Kazi AB, Li Z, Avery M, Peraud O, Hill RT, Franzblau SG, Zhang F, Schinazi RF, Wirtz SS, Tharnish P, Kelly M, Wahyuono S, Hamann MT. Manadomanzamines A and B: A Novel Alkaloid Ring System with Potent Activity against Mycobacteria and HIV-1. J Am Chem Soc. 2003; 125(44):13382-13386.
 94. Koh S-I, Shin H-S. The Anti-Rotaviral and Anti-Inflammatory Effects of *Hyrtios* and *Haliclona* Species. J Microbiol Biotechnol. 2016; 26(11):2006-11.
 95. Ichiba T, Yoshida WY, Scheuer PJ, Higa T, Gravalos DG. Hennoxazoles, bioactive bisoxazoles from a marine sponge. J Am Chem Soc. 1991; 113(8):3173-4.
 96. Keifer PA, Schwartz RE, Koker MES, Hughes RG, Rittschof D, Rinehart KL. Bioactive Bromopyrrole Metabolites from the Caribbean Sponge *Agelas conifera*. J Org Chem. 1991; 56(9):2965-2975.

97. Kohmoto S, Mcconnell OJ, Wright A, Cross S. Isospongiadiol, a Cytotoxic and Antiviral Diterpene from a Caribbean Deep Water Marine Sponge, *Spongia* sp. Chem Lett. 1987; 16(9):1687-1690.
98. Al-Massarani SM, El-Gamal AA, Al-Said MS, Al-Lihaibi SS, Basoudan OA. *In vitro* cytotoxic, antibacterial and antiviral activities of triterpenes from the Red Sea sponge, *Siphonochalina siphonella*. Trop J Pharm Res. 2015; 14(1):33-40.
99. Gong KK, Tang XL, Liu YS, Li PL, Li GQ. Imidazole alkaloids from the South China Sea sponge *Pericharax heteroraphis* and their cytotoxic and antiviral activities. Molecules. 2016;21(2):150-157.
100. Walag AMP, del Rosario RM. Total Flavonoids Content, Total Phenolics Content, and Antioxidant Activities of *Acanthaster planci* and *Linckia laevigata* collected from Carmen, Agusan del Norte, Philippines. Malays J Biochem Mol Biol. 2020;23(1):77-85.
101. Walag AMP, del Rosario RM. Proximate biochemical composition and brine shrimp lethality assay of selected sea stars from Goso-on and Vinapor, Carmen, Agusan del Norte, Philippines. Malays J Biochem Mol Biol. 2018; 21(3):11-8.
102. Walag AMP, Kharwar RN. Assessment of Crude Extract Yield and In-vitro Antioxidant Activity of Sea Star from Philippines. Uttar Pradesh J of Zoo. 2021; 42(22):68-76.
103. Walag AMP, del Rosario RM. Initial evaluation of metal content of *Acanthaster planci* and *Linckia laevigata* collected from Carmen, Agusan del Norte, Philippines. Malays J Biochem Mol Biol. 2020; 20(3):1-7.
104. Farshadpour F, Gharibi S, Taherzadeh M, Amirinejad R, Taherkhani R, Habibian A, Zandi K. Antiviral activity of *Holothuria* sp. a sea cucumber against herpes simplex virus type 1 (HSV-1). Eur Rev Med Pharmacol Sci. 2014; 18:333-337.
105. Pujol CA, Ray S, Ray B, Damonte EB. Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides. Int J Biol Macromol. 2012; 51(4):412-416.
106. Lu Y, Wang B-L. The Research Progress of Antitumorous Effectiveness of *Stichopus japonicus* Acid Mucopolysaccharide in North of China. Am J Med Sci. 2009; 337(3):195-8.
107. Maier MS, Roccatagliata AJ, Kuriss A, Chludil H, Seldes AM, Pujol CA, Damonte EB. Two new cytotoxic and virucidal trisulfated triterpene glycosides from the antarctic sea cucumber *Staurocucumis liouvillei*. J Nat Prod. 2001; 64(6):732-6.
108. Tsushima M, Fujiwara Y, Matsuno T. Novel marine di-Z-carotenoids: Cucumariaxanthins A, B, and C from the sea cucumber *Cucumaria japonica*. J Nat Prod. 1996; 59(1):30-34.
109. Tripoteau L, Bedoux G, Gagnon J, Bourgougnon N. In vitro antiviral activities of enzymatic hydrolysates extracted from byproducts of the Atlantic holothurian *Cucumaria frondosa*. Process Biochemistry. 2015. Doi: 10.1016/j.procbio.2015.02.012.
110. Huang N, Wu M-Y, Zheng C-B, Zhu L, Zhao J-H, Zheng Y-T. The depolymerized fucosylated chondroitin sulfate from sea cucumber potently inhibits HIV replication via interfering with virus entry. Carbohydr Res. 2013; 380:64-9.
111. Roccatagliata AJ, Maier MS, Seldes AM, Pujol CA, Damonte EB. Antiviral Sulfated Steroids from the Ophiuroid *Ophioplocus januarii*. J Nat Prod. 1996; 59(9):887-9.
112. Comin MJ, Maier MS, Roccatagliata AJ, Pujol CA, Damonte EB. Evaluation of the antiviral activity of natural sulfated polyhydroxysteroids and their synthetic derivatives and analogs. Steroids. 1999; 64(5):335-40.
113. Peng Y, Zheng J, Huang R, Wang Y, Xu T, Zhou X, Liu Q, Zeng F, Ju H, Yang X, Liu Y. Polyhydroxy steroids and saponins from China Sea starfish *Asterina pectinifera* and their biological activities. Chem Pharm Bull (Tokyo). 2010;58(6):856-858.
114. Jha R, Zi-rong X. Biomedical Compounds from Marine organisms. Mar Drugs. 2004; 2(3):123-146.
115. Wijanarko A, Lischer K, Hermansyah H, Pratami DK, Sahlan M. Antiviral activity of *Acanthaster planci* phospholipase A2 against human immunodeficiency virus. Vet World. 2018; 11(6):824-9.
116. Salas-Rojas M, Galvez-Romero G, Anton-Palma B, Acevedo R, Blanco-Favela F, Aguilar-Setién A. The coelomic fluid of the sea urchin *Tripleneustes depressus* shows antiviral activity against Suid herpesvirus type 1 (SHV-1) and rabies virus (RV). Fish Shellfish Immunol. 2014; 36(1):158-163.
117. Fedoreyev S, Krylova N, Mishchenko N, Vasileva E, Pisyagin E, Iunikhina O, Lavrov V, Svitich O, Ebralidze L, Leonova G. Antiviral and Antioxidant Properties of Echinochrome A. Mar Drugs. 2018; 16(12):509.
118. Laille M, Gerald F, Debitus C. In vitro antiviral activity on dengue virus of marine natural products. Cell Mol Life Sci. 1998;54(2):167-70.
119. Dong G, Xu T, Yang B, Lin X, Zhou X, Yang X, Liu Y. Chemical constituents and bioactivities of starfish. Chem Biodivers. 2011; 8(5):740-91.
120. McKee TC, Cardellina JH, Riccio R, D'Auria MV, Iorizzi M, Minale L, Moran RA, Gulakowski RJ, McMahon JB. HIV-Inhibitory Natural Products. 11. Comparative Studies of Sulfated Sterols from Marine Invertebrates. J Med Chem. 1994; 37(6):793-7.
121. Savidov N, Glorizova TA, Dem-bitsky VM. Pharmacological activities of sulphated steroids derived from marine sources. Life Science Press. 2018; 2(1):48-58.
122. Nakao Y, Masuda A, Matsunaga S, Fusetani N. Pseudotheonamides, serine protease inhibitors from the marine sponge *Theonella swinhoei*. J Am Chem Soc. 1999; 121(11):2425-2431.
123. Khan MT, Ali A, Wang Q, Irfan M, Khan A, Zeb MT, Zhang YJ, Chinnasamy S, Wei DQ. Marine natural compounds as potent inhibitors against the main protease of SARS-CoV-2—a molecular dynamic study. J Biomol Struct Dyn. 2020; 39(10):3627-3637. Doi: 10.1080/07391102.2020.1769733.
124. Jiménez C. Marine Natural Products in Medicinal Chemistry. ACS Med Chem Lett. 2018; 9(10):959-961.
125. Pereira L, Critchley AT. The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times? J Appl Phycol. 2020; 32(3):1875-1877.